Compare Pfizer Inc (PFE) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vale SA — how do they compare? Pfizer Inc trades at $28.19 (market cap $158.56B), while Vale SA trades at $13.54 (market cap $57.32B). The key difference: Pfizer Inc is far larger — about 2.8× Vale SA's market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vale SA for 109 Days on average.
| PFE | VALE | |
|---|---|---|
Market Cap | $158.56B | $57.32B |
Volume | 44,138,282 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $29.02 | $17.82 |
52-Week Low | $23.67 | $10.75 |
Typical Hold Time | 158 Days | 109 Days |
Enterprise Value | $210.06B | $73.56B |
Dividend Yield | 6.18% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
VALE trades at $13.50, down 0.81% with bearish technical signals. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 EPS expected at $0.42. Revenue declined from $43.8B in 2022 to $38.4B in 2025, though 2026 projections show a slight recovery to $41.2B. Analyst consensus is mixed with 32% buy ratings but a $16.21 price target suggesting 20% upside. Recent news highlights cost pressures and regulatory risks in Brazil.
VALE faces headwinds from declining iron ore margins and rising operational costs, but maintains strong cash flow and dividend payments. The base metals segment shows growth potential, though cyclical exposure and Brazilian regulatory uncertainty pose significant risks. With current valuation metrics appearing reasonable (P/E 26.8, P/B 1.5), the stock offers value for patient investors willing to navigate commodity volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
